Skip to main content
Daniela Hoehn, MD, Pathology, New York, NY

DanielaHoehnMDPhD, FACP

Pathology New York, NY

Hematopathology, Anatomic Pathology, Clinical Pathology, Surgical Pathology

SENIOR MEDICAL DIRECTOR

Dr. Hoehn is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Hoehn's full profile

Already have an account?

Education & Training

  • University of Texas M D Anderson Cancer Center
    University of Texas M D Anderson Cancer CenterHematopathology, 2010 - 2012
  • Icahn School of Medicine at Mount Sinai/Morningside/West
    Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Pathology-Anatomic and Clinical, 2006 - 2010
  • Montefiore Medical Center/Albert Einstein College of Medicine
    Montefiore Medical Center/Albert Einstein College of MedicineResidency, Surgery, 2005 - 2006
  • Johannes Gutenberg University of Mainz Faculty of Medicine
    Johannes Gutenberg University of Mainz Faculty of MedicineClass of 2004

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2012 - 2026
  • NY State Medical License
    NY State Medical License 2014 - 2024
  • PA State Medical License
    PA State Medical License 2009 - 2018
  • American Board of Pathology Pathology - Anatomic/Pathology - Clinical
  • American Board of Pathology Hematopathology

Publications & Presentations

PubMed

Abstracts/Posters

  • Daratumumab (DARA) Maintenance Therapy Improves Depth of Response and Results in Durable Progression-free Survival (PFS) Following DARA plusCyclophosphamide, Bortezomi...
    Robert M. Rifkin, Jason Melear, Edward Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don Stevens, Sriya Gunawardena, Daniela Hoehn, Yana Lutska, Keqin Qi, ..., ASH 2019, Orlando, 12/9/2019
  • Depth of Response to Daratumumab (DARA), Lenalidomide, Bortezomib, and Dexamethasone (RVd) Improves over Time in Patients (pts) with Transplant-Eligible Newly Diagnose...
    Daniela Hoehn, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • Efficacy and Updated Safety Analysis of a Safety Run-in Cohort from Griffin, a Phase 2 Randomized Study of Daratumumab ﴾Dara﴿, Bortezomib ﴾V﴿, Lenalidomide ﴾R﴿, and De... 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018